Peptide YY (PYY) is a 36 amino acid gastrointestinal peptide discovered in 1982 by Tatemoto and co-workers. 1 It is produced by enteroendocrine L cells of the hindgut mucosa, 2 and is also found in the enteric nervous system. 3 It is a member of the PP fold peptide family, which includes neuropeptide Y (NPY), a neuropeptide widely present in central and peripheral nervous systems, and pancreatic polypeptide (PP). 4 PYY release is stimulated by several factors, including the presence of nutrients in the duodenum or in the distal part of the gut. 5 Potent PYY releasers are amino acids 6 and short chain fatty acids [7] [8] [9] present in the large intestine. PYY displays several physiological functions throughout the gut including secretory and motor activities. Centrally injected into rats, this peptide inhibits gastric emptying through a cholinergic nervous pathway in vivo, 10 and stimulates phasic activity of rat duodenum in vivo. 11 In the isolated perfused canine ileum, it stimulates phasic contractions through inhibition of nitric oxide release and stimulation of acetylcholine release. 12 Concerning the colon, PYY and NPY have been shown to inhibit colonic motility in cats in vivo 13 and in guinea pigs in vitro.
14 Two distinct mechanisms may exist: NPY may stimulate noradrenaline (norepinephrine) release, which inhibits acetylcholine secretion, whereas PYY directly inhibits acetylcholine secretion by a presynaptic receptor on cholinergic neurones. Wager-Pagé and co workers 11 showed in rats a stimulatory eVect of PYY in vivo, and a recent study by our team showed that PYY is implicated in the short chain fatty acid induced inhibition of myoelectric colonic activity. 9 PYY and related peptides exert their eVects through several receptors (for reviews, see 15 and 16 ), together named the Y receptor family. So far, six Y receptors have been identified; five of them have been cloned and four (Y1, Y2, Y5, and Y6) are able to bind PYY with high aYnity. The Y3 receptor has been pharmacologically described as being specific for NPY, but has not yet been cloned. The Y4 receptor, also called PP1 receptor, binds PP with high aYnity, whereas it has a weaker aYnity for PYY and NPY. In mice, the Y6 receptor has recently been cloned but the agonist potency remains unclear. In humans, such a receptor has also been found, but in a truncated non-functional form. However, in rats, this receptor has not been found in any tissue. 17 In addition, a PYY preferring receptor has also been described in the epithelium of the rat small intestine, but has not yet been cloned. 18 All the cloned receptors belong to the G protein coupled receptor family and seem to be linked to G i /G 0 proteins.
The aims of this study were to characterise the eVects of PYY on the motility of rat proximal colon in vitro and to elucidate the pathways and receptors involved.
Materials and methods

MEASUREMENT OF STRIP CONTRACTIONS
Male Wistar rats were used following the guiding principles in the care and use of animals described in the Declaration of Helsinki. Animals were killed by stunning and cervical dislocation. A median laparotomy was performed, and the external side of the proximal colon was peeled and cut into 1-1.5 cm long strips of nerve and muscle, referred to as the nerve/muscle preparation, as described elsewhere. 19 These preparations included both plexuses and muscular layers, and were oriented longitudinally in 37°C warmed 5 ml organ baths, containing oxygenated Krebs bicarbonate buVer. BuVer was composed of (mM): NaCl (128), KCl (4.5), CaCl 2 (2.5), MgSO 4 (1.18), KH 2 PO 4 (1.18), NaHCO 3 (25) , glucose (11) . A tension of 1 g was applied to the strips, and a one hour equilibration period was allowed. An isometric transducer, linked to the preparation, was used to record strip contractile activity. Before and after each experiment, KCl 40 mM and acetylcholine chloride (ACh) 10 −6 M were added successively to test strip functionality. The resulting contraction was used to express our results as a percentage of a 10 −6 M ACh induced contraction. Then, strips were rinsed three times with buVer, and a 20 minute recovery period was allowed. PYY was used at increasing concentrations in a cumulative manner (10 −8 -10 −5 M). To investigate the receptor involved in the PYY induced contraction of colonic strips, agonists and antagonists for Y receptors were used (table 1). The specific nerve blocker tetrodotoxin was used to determine the nervous part of the PYY eVect. Finally, antagonists for contractile mediator receptors were used to examine the mechanism of action of PYY: atropine, a muscarinic receptor antagonist; hexamethonium, a nicotinic receptor antagonist; methiotepin, a 5-hydroxytryptamine (5HT) 1 20 and spectrophotometrically quantified. RNA isolated from rat brain was used as a positive control of expression of all Y receptor subtypes. cDNA synthesis was performed with 1 µg total RNA using random primers and murine Moloney leukaemia virus reverse transcriptase according to the manufacturer's instructions (Gibco-BRL, Cergy Pontoise, France). PCR was performed using 1 µl of the reverse transcription reaction mixture, 0.5 unit Gold Star DNA polymerase (Eurogentec, Seraing, Belgium), 3 µl 25 mM MgCl 2 , 1 µl 10 mM dNTPs, 5 µl 10 × Goldstar DNA polymerase buVer, and 50 pmol of each sense and antisense primer under the following conditions (35 cycles): 92°C for 40 seconds, 58°C for 40 seconds, and 72°C for 50 seconds. Primers for Y1, Y2, Y4, and Y5 receptors and for glyceraldehyde-3-phosphate dehydrogenase (Genosys, Pampisford, UK) as housekeeping gene were used (table 2). As the rat Y2 receptor has not yet been cloned, we used primers for the Y2 receptor as described by Goumain and co-workers. 21 PCR products were separated on 2% agarose gel and stained with ethidium bromide.
ISOLATION OF COLONIC SMOOTH MUSCLE CELLS
Smooth muscle cells were isolated as described previously by Blottière and co-workers. 22 Briefly, strips from the colon muscle layer were removed and maintained in PSS/Hepes buVer (NaCl 130 mM; KCl 5.6 mM, Hepes 8 mM, glucose 2 g/l; pH 7.4), containing 2 mM Ca 2+ /1 mM Mg 2+ . Strips were then cut into small pieces and incubated at 37°C for two periods of 30 minutes in a Ca 2+ -free collagenase solution: phosphate buVered saline/2% bovine serum albumin/0.1% collagenase/0.05% soybean trypsin inhibitor/ 0.01% Pronase. Then, the tissue was rinsed with collagenase-free buVer. Strip pieces were recovered by centrifugation, and cells were dispersed by gently pipetting into PSS/Hepes/0.8 mM Ca
2+
. Cell contraction was measured at room temperature, in the presence of PYY or ACh, Figure 1 (A one third of the PYY induced contractions, suggesting involvement of the enteric nervous system in the PYY eVect (table 3) . Hexamethonium 3 × 10 −4 M was also a moderate inhibitor of the PYY induced contraction, but had no eVect on muscle basal activity. SR 140333 3 × 10 −7 M, an NK1 receptor antagonist, also significantly reduced the PYY induced contraction. Atropine 10 −6 M induced slight, but not significant, inhibition of the PYY eVect. Finally, methiotepin and the NK2 receptor antagonist SR 48968 had no eVect on the nerve/muscle preparation basal activity and on the tonic contraction evoked by PYY.
EFFECT OF PYY ON COLONIC SMOOTH MUSCLE CELL LENGTH
The application of 10 −6 M PYY to freshly isolated colonic smooth muscle cells induced a reduction in cell length as compared with control cells exposed to buVer (65.5 (2.9) µm (n = 60) v 77.2 (3.7) µm (n = 60) respectively, p<0.01; fig 2) . ACh 10 −6 M also significantly reduced smooth muscle cell length (64.2 (3.5) µm (n = 60) compared with control cells, p<0.001). This reduction in cell length reflected contraction of the smooth muscle cells when exposed to PYY. . This eVect was partly blocked by tetrodotoxin (data not shown). In contrast, the Y2 agonist NPY , which is also a partial Y5 agonist, was unable to elicit any motor eVect on the proximal colon nerve/muscle preparation (fig 4) , even when tested at high concentration (10 −5 M). Thus it is unlikely that the PYY eVect occurs through a Y2 or Y5 receptor.
The dose-response curve elicited by PP was leftward shifted as compared with that of PYY ( fig 5A) . However, it was strongly blocked by tetrodotoxin application. Thus, a Y4 receptor seemed to be localised on the enteric nerves.
NPY induced a dose dependent contraction with the same potency as PYY (fig 5B) , and tetrodotoxin application blocked its eVects at around the same level as the PYY induced contraction.
BIBP 3226, a selective Y1 receptor antagonist, did not aVect the PYY induced contraction at any of the doses tested (10 coworkers. 24 Thus, this receptor did not seem to play a significant role in the contractile eVect of PYY.
Finally, RT-PCR was performed on the proximal colon nerve/muscle preparation using specific primers for Y1, Y2, Y4, and Y5 receptors. The presence of mRNA coding for Y1 and Y4 receptors, but not for Y2 and Y5 receptors, was established ( fig 6) .
Discussion
PYY is a well known modulator of gastrointestinal function, including motility, but little is known about its colonic motor eVects. Our study aimed to characterise the eVects of PYY on rat colon, using nerve/muscle preparations. This model allowed us to bypass the potential systemic eVects of circulating hormones and brain regulation associated with an in vivo study. Our results show that PYY induces dose dependent contraction of rat proximal colon in vitro.
Nerve blocking by tetrodotoxin resulted in an increase in the frequency and amplitude of spontaneous contractions. Such an eVect has been described for cat colon. 25 Moreover, in a recent study investigating the neuronal immunoreactivity for diVerent neurotransmitters in the plexus of the colon, a predominance of inhibitory pathways, especially neurones expressing mRNA for NO synthase, was found in the proximal colon. 26 Thus nerve blocking by tetrodotoxin may inactivate this basal inhibition of proximal colon activity, explaining this observation. Tetrodotoxin inhibited one third of the PYY induced contractions of the rat colon nerve/muscle preparation, indicating partial involvement of the enteric nervous system. Hexamethonium produced a similar inhibition. Acetylcholine is known to play an important role in neurone-neurone transmission through nicotinic receptors; thus the breakdown of this cholinergic outflow may inhibit the release of several neurotransmitters acting on colonic motility. In our study, acetylcholine release in the neuromuscular junction after PYY application seemed weak, as atropine inhibited about 10% of the colonic response and this inhibition was not significant. The NK1 and NK2 receptors are both known to be present in rat proximal colon and play a role in colonic motility. 27 The NK1 receptor antagonist SR 140333 moderately inhibited the PYY eVect, whereas the NK2 receptor antagonist SR 48968 was devoid of eVect. Substance P, the strongest endogenous agonist for the NK1 receptor, may be a mediator of the PYY eVect. With respect to the 5HT receptors, the 5HT 1 and 5HT 2 subtypes have been shown to be the most eVective in mediating 5HT induced rat proximal colon contraction. 28 In our study, the 5HT 1/2 antagonist methiotepin was ineVective, showing lack of involvement of 5HT in the PYY eVect. Thus the nervous part of the action of PYY on colonic motor activity seems to be complex. Nevertheless, it involves nicotinic interneurones and neurokininergic motoneurones.
Some of the action of PYY on colon smooth muscle is exerted on the smooth muscle cells, as its application resulted in a decrease in cell length, indicating myocyte contraction. To our knowledge, this is the first study to show clearly a direct contractile eVect of PYY on smooth muscle cells freshly isolated from a gastrointestinal tissue.
Blocking 30 We next investigated the receptors involved in the PYY mediated contraction using pharmacological tools. PP applied to proximal colon muscle showed a leftward shift of the dose-response curve, compared with that of PYY and NPY, which was mainly blocked by tetrodotoxin. According to Lundell and co-workers, 31 PP has a 10 000-fold higher aYnity for the Y4 receptor than PYY and NPY, which explains this shift. These results, reinforced by the presence of mRNA encoding the Y4 receptor, suggest the involvement of a nervous Y4 receptor, but the eVect of PYY on rat colon implies that this is unlikely to be the only receptor. As NPY induced a contraction with the same potency as PYY, and tetrodotoxin application blocked the muscle response to NPY and PYY to a similar extent, we suggest that the other receptor involved is located on the smooth muscle cell and has the same aYnity for these two peptides. As shown in table 1, Y1, Y2, and Y5 receptors display such properties. The Y2 receptor agonist, and to a lesser 15 but a recent study documents its absence from rats. 17 Moreover, it has been found in a truncated non-functional form in the gastrointestinal tract in humans. Our hypothesis is reinforced by a recent study that failed to detect any Y1 receptor on Wistar rat colonic smooth muscle cells using immunohistochemistry. 32 Another recent study on the receptors involved in NPY induced contraction corroborates in part the present work. 33 Indeed, the authors found a nervous Y4 receptor and a lack of eVect of BIBP 3226. However, in contrast with our study, NPY(13-36) also induced a contraction, which was unaVected by tetrodotoxin but strongly inhibited by atropine, associated with the presence of mRNA encoding the Y2 receptor. It is noteworthy that this study was performed in Sprague-Dawley rats, whereas we used Wistar rats. This diVerence in strain may explain why the results are closely related but not identical.
In conclusion, we show that PYY, a peptide released by enteroendocrine L cells, stimulates proximal colon motility in vitro in rats. We can suggest two pathways for this eVect: firstly, a nervous pathway involving a Y4 receptor which stimulates nicotinic transmission in enteric plexuses; these interneurones then stimulate motorneurones; secondly, a direct eVect exerted by PYY on colonic smooth muscle cells, which results in the opening of L-type Ca 2+ channels. The receptor involved is a Y1-like receptor which is not the Y6 receptor described in mice and humans, and therefore may be a new member of the Y receptor family.
